Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Chinese Medicine
Published in: Chinese Medicine 1/2018

Open Access 01-12-2018 | Research

Gut microbiota was modulated by moxibustion stimulation in rats with irritable bowel syndrome

Authors: Xiaomei Wang, Qin Qi, Yuanyuan Wang, Huangan Wu, Xiaoming Jin, Huan Yao, Duiyin Jin, Yanan Liu, Cun Wang

Published in: Chinese Medicine | Issue 1/2018

Login to get access

Abstract

Background

The pathogenesis of irritable bowel syndrome (IBS) is closely related to intestinal dysbacteriosis and can be controlled by moxibustion treatment. However, the mechanism underlying the therapeutic value of moxibustion in IBS treatment remains unknown.

Methods

An IBS rat model was established by colorectal distention (CRD) stimulus and mustard oil clyster. Sixty-five male rats were randomly divided into six groups: normal, IBS model, moxibustion, electroacupuncture (EA), Bifid-triple Viable Capsule (BTVC) and Pinaverium Bromide (PB) groups. The moxibustion group was treated with mild moxibustion at the bilateral Tianshu (ST25) and Shangjuxu (ST37) for 10 min/day for 7 days, the EA group was given EA at ST25 and ST37 once daily for 7 days, while the BTVC group and PB groups received Bifid-triple Viable Capsule and Pinaverium Bromide solution (at the proportion of 1:0.018) respectively by gavage once daily for 7 days. After the treatment, abdominal withdrawal reflex (AWR) scores were determined based on CRD stimulus, gut microbiota profiling was conducted by 16S rRNA high-throughput sequencing.

Results

Irritable bowel syndrome model rats had significantly increased AWR scores at all intensities (20, 40, 60 and 80 mmHg) compared with the normal group. Moxibustion treatment significantly reduced AWR scores compared with the IBS model group at all intensities. Across all groups the most abundant phyla were Bacteroidetes and Firmicutes followed by Proteobacteria and Candidatus Saccharibacteria. At genus level IBS model rats had a higher abundance of Prevotella, Bacteroides and Clostridium XI and a lower abundance of Lactobacillus and Clostridium XIVa compared with normal rats. These changes in microbiota profiles could however be reversed by moxibustion treatment. Alpha diversity was decreased in IBS model rats compared with normal rats, yet significantly increased in moxibustion- and PB-treated rats compared with IBS rats.

Conclusion

Our findings suggest that moxibustion treats IBS by modulating the gut microbiota.
Appendix
Available only for authorised users
Literature
1.
2.
Zeber-Lubecka N, Kulecka M, Ambrozkiewicz F, Paziewska A, Goryca K, Karczmarski J, et al. Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome. Gut Microbes. 2016;7:397–413.CrossRef
3.
Lee OY. Asian motility studies in irritable bowel syndrome. J Neurogastroenterol Motil. 2010;16:120–30.CrossRef
4.
Barshop K, Staller K. New pathways, new targets: visceral hypersensitivity pathogenesis in irritable bowel syndrome. Clin Transl Gastroenterol. 2016;7:e146.CrossRef
5.
Lee YJ, Paek KS. Irritable bowel syndrome: emerging paradigm in pathophysiology. World J Gastroenterol. 2014;20:2456–69.CrossRef
6.
Ratanasirintrawoot S, Israsena N. Stem cells in the intestine: possible roles in pathogenesis of irritable bowel syndrome. J Neurogastroenterol Motil. 2016;22:267–382.CrossRef
7.
Ringel Y, Maharshak N. Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2013;305:529–41.CrossRef
8.
Bennet S, Öhman L, Simrén M. Gut microbiota as potential orchestrators of irritable bowel syndrome. Gut Liver. 2015;9:318–31.CrossRef
9.
Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, et al. A human gut microbial gene catalog established by metagenomic sequencing. Nature. 2010;464:59–65.CrossRef
10.
Khan I, Yasir M, Azhar EI, Kumosani T, Barbour EK, Bibi F, et al. Implication of gut microbiota in human health. CNS Neurol Disord Drug Targets. 2014;13:1325–33.CrossRef
11.
Ubeda C, Pamer EG. Antibiotics, microbiota, and immune defense. Trends Immunol. 2012;33:459–66.CrossRef
12.
Huang Y, Chen Z. Inflammatory bowel disease related innate immunity and adaptive immunity. Am J Transl Res. 2016;8:2490–7.PubMedPubMedCentral
13.
Penders J, Gerhold K, Thijs C, Zimmermann K, Wahn U, Lau S, et al. New insights into the hygiene hypothesis in allergic diseases: mediation of sibling and birth mode effects by the gut microbiota. Gut Microbes. 2014;5:239–44.CrossRef
14.
Pickett-Blakely O. Obesity and irritable bowel syndrome: a comprehensive review. Gastroenterol Hepatol. 2014;10:411–6.
15.
Marchesi JR, Dutilh BE, Hall N, Peters WH, Roelofs R, Boleij A, et al. Towards the human colorectal cancer microbiome. PLoS ONE. 2011;6:e20447.CrossRef
16.
Lopetuso LR, Scaldaferri F, Bruno G, Petito V, Franceschi F, Gasbarrini A. The therapeutic management of gut barrier leaking: the emerging role for mucosal barrier protectors. Eur Rev Med Pharmacol Sci. 2015;19:1068–76.PubMed
17.
Zhu LM, Huang D, Shi LL, Liang LX, Xu T, Chang M, et al. Intestinal symptoms and psychological factors jointly affect quality of life of patients with irritable bowel syndrome with diarrhea. Health Qual Life Outcomes. 2015;13:49.CrossRef
18.
Shi Y, Chen YH, Yin XJ, Wang AQ, Chen XK, Lu JH, et al. Electroacupuncture versus moxibustion for irritable bowel syndrome: a randomized, parallel-controlled trial. Evid Based Complement Altern Med. 2015;2015:361786.
19.
Yoon SL, Grundmann O, Koepp L, Farrell L. Management of irritable bowel syndrome (IBS) in adults: conventional and complementary/alternative approaches. Altern Med Rev. 2011;16:134–51.PubMed
20.
Chiu JH. How does moxibustion possibly work? Evid Based Complement Altern Med. 2013;2013:198584.CrossRef
21.
Huang RJ, Zhao JM, Wu LY, Dou CZ, Liu HR, Weng ZJ, et al. Mechanisms underlying the analgesic effect of moxibustion on visceral pain in irritable bowel syndrome: a review. Evid Based Complement Altern Med. 2014;2014:895914.
22.
Wang XM, Lu Y, Wu LY, Yu SG, Zhao BX, Hu HY, et al. Moxibustion inhibits interleukin-12 and tumor necrosis factor alpha and modulates intestinal flora in rat with ulcerative colitis. World J Gastroenterol. 2012;18:6819–28.CrossRef
23.
Al-Chaer ED, Kawasaki M, Pasricha PJ. A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development. Gastroenterology. 2000;119:1276–85.CrossRef
24.
Weng ZJ, Wu LY, Zhou CL, Dou CZ, Shi Y, Liu HR, et al. Effect of electroacupuncture on P2X3 receptor regulation in the peripheral and central nervous systems of rats with visceral pain caused by irritable bowel syndrome. Purinergic Signal. 2015;11(3):321–9.CrossRef
25.
Takahashi S, Tomita J, Nishioka K, Hisada T, Nishijima M. Development of a prokaryotic universal primer for simultaneous analysis of Bacteria and Archae using next-generation sequencing. PLoS ONE. 2014;9:e105592.CrossRef
26.
Vicente CS, Ozawa S, Hasegawa K. Composition of the cockroach gut microbiome in the presence of parasitic nematodes. Microbes Environ. 2016;31:314–20.CrossRef
27.
Xu J, Chen X, Yu S, Su Y, Zhu W. Effects of early intervention with sodium butyrate on gut microbiota and the expression of inflammatory cytokines in neonatal piglets. PLoS ONE. 2016;11:e0162461.CrossRef
28.
Wang Q, Garrity GM, Tiedje JM, Cole JR. Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol. 2007;73:5261–7.CrossRef
29.
Keszthelyi D, Troost FJ, Masclee AA. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Methods to assess visceral hypersensitivity in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2012;303:141–54.CrossRef
30.
Zhao JM, Chen L, Zhou CL, Shi Y, Li YW, Shang HX, et al. Comparison of electroacupuncture and moxibustion for relieving visceral hypersensitivity in rats with constipation-predominant irritable bowel syndrome. Evid Based Complement Altern Med. 2016;2016:9410505.
31.
Cui S, Hu Y. Multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Int J Clin Exp Med. 2012;5(3):238–44.PubMedPubMedCentral
32.
Hou X, Chen S, Zhang Y, Sha W, Yu X, Elsawah H, et al. Quality of life in patients with irritable bowel syndrome (IBS), assessed using the IBS–quality of life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: results of an international prospective observational cohort study in Poland, Egypt, Mexico and China. Clin Drug Invest. 2014;34(11):783–93.CrossRef
33.
Zeng MY, Cisalpino D, Varadarajan S, Hellman J, Warren HS, Cascalho M, et al. Gut microbiota-induced immunoglobulin G controls systemic infection by symbiotic bacteria and pathogens. Immunity. 2016;44:647–58.CrossRef
34.
Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature. 2013;504:446–50.CrossRef
35.
Zhang HS, Wang FC. Application of combination of he-mu points and combination of shu-yuan in syndrome differentiation of zang- and fu-organs. Zhongguo Zhen Jiu. 2006;26(5):378–80.PubMed
36.
Öhman L, Törnblom H, Simrén M. Crosstalk at the mucosal border: importance of the gut microenvironment in IBS. Nat Rev Gastroenterol Hepatol. 2015;12:36–49.CrossRef
37.
Kondo T, Kawamoto M. Acupuncture and moxibustion for stress-related disorders. Biopsychosoc Med. 2014;8:7.CrossRef
38.
Ponnusamy K, Choi JN, Kim J, Lee SY, Lee CH. Microbial community and metabolomic comparison of irritable bowel syndrome faeces. J Med Microbiol. 2011;60:817–27.CrossRef
39.
Goepp J, Fowler E, McBride T, Landis D. Frequency of abnormal fecal biomarkers in irritable bowel syndrome. Glob Adv Health Med. 2014;3:9–15.CrossRef
40.
Sheikh Sajjadieh MR, Kuznetsova LV, Bojenko VB. Dysbiosis in ukrainian children with irritable bowel syndrome affected by natural radiation. Iran J Pediatr. 2012;22:364–8.PubMed
41.
Patel R, DuPont HL. New approaches for bacteriotherapy: prebiotics, new-generation probiotics, and synbiotics. Clin Infect Dis. 2015;60:108–21.CrossRef
42.
Kianifar H, Jafari SA, Kiani M, Ahanchian H, Ghasemi SV, Grover Z, et al. Probiotic for irritable bowel syndrome in pediatric patients: a randomized controlled clinical trial. Electron Physician. 2015;7:1255–60.PubMedPubMedCentral
43.
Shavakhi A, Minakari M, Farzamnia S, Peykar MS, Taghipour G, Tayebi A, et al. The effects of multi-strain probiotic compound on symptoms and quality-of-life in patients with irritablebowel syndrome: a randomized placebo-controlled trial. Adv Biomed Res. 2014;3:140.CrossRef
44.
Tiequn B, Guanqun C, Shuo Z. Therapeutic effects of Lactobacillus in treating irritable bowel syndrome: a meta-analysis. Intern Med. 2015;54:243–9.CrossRef
Metadata
Title
Gut microbiota was modulated by moxibustion stimulation in rats with irritable bowel syndrome
Authors
Xiaomei Wang
Qin Qi
Yuanyuan Wang
Huangan Wu
Xiaoming Jin
Huan Yao
Duiyin Jin
Yanan Liu
Cun Wang
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Chinese Medicine / Issue 1/2018
Electronic ISSN: 1749-8546
DOI
https://doi.org/10.1186/s13020-018-0220-y

Other articles of this Issue 1/2018

Chinese Medicine 1/2018 Go to the issue

Research

A network pharmacology approach to explore the mechanisms of Erxian decoction in polycystic ovary syndrome

Review

Internationalization of Traditional/Complementary Medicine products: market entry as medicine

Review

Indigenous medicinal plants of Pakistan used to treat skin diseases: a review

Research

Isorhynchophylline alleviates learning and memory impairments induced by aluminum chloride in mice

Research

Bioaccessibility and risk assessment of heavy metals, and analysis of arsenic speciation in Cordyceps sinensis

Review

Techniques for extraction and isolation of natural products: a comprehensive review